Cohance Lifesciences Limited
Invesco Mutual Fund increased its stake in Cohance Lifesciences from 1.44% to 1.69%, buying 974,617 shares. The additional shares are worth ₹43.09 crore at a price of ₹441.90 apiece.
A Hyderabad-based contract development and manufacturing organization serving leading global pharmaceutical and fine chemical companies. Cohance Life provides integrated services spanning process research and development through late-stage clinical and commercial manufacturing for new chemical entities. The company distinguishes itself through its commitment to delivering customized solutions that fulfill specific customer needs and expectations across the entire drug development lifecycle.
Indian subsidiary of Invesco Ltd, a US-listed global investment manager with over USD 1.8 trillion in AUM worldwide. Manages over Rs 1.2 lakh crore in India. Known for its Invesco India Contra Fund, which runs a contrarian, undervalued stock strategy against consensus market positioning. One of the few global AMC franchises maintaining a strong active equity presence in India.